53320 Federal Register / Vol. 75, No. 168 / Tuesday, August 31, 2010 / Notices 

hereby given of meetings of the National 

Advisory Neurological Disorders and 

Stroke Council. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council 

Training, Career Development, and Special 

Programs Subcommittee. 

Date: September 22, 2010. 

Open: 6 p.m. to 7 p.m. 

Agenda: To discuss the training plan of the 

institute. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Closed: 7 p.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Stephen J. Korn, PhD, 

Director, Training and Special Programs 

Officer, National Institute of Neurological 

Disorders and Stroke, National Institutes of 

Health, 6001 Executive Blvd., Suite 2154, 

MSC 9527, Bethesda, MD 20892–9527, (301) 

496–4188. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council; 

Basic and Preclinical Programs 

Subcommittee. 

Date: September 23, 2010. 

Time: 8 a.m. to 9:30 a.m. 

Agenda: To discuss basic and preclinical 

programs policy. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, 

Conference Room F1/F2, Bethesda, MD 

20892. 

Contact Person: William D. Matthew, PhD, 

Director, Office of Translational Research, 

NINDS, National Institutes of Health, 

Neuroscience Center, Room 2137, 6001 

Executive Blvd., (301) 496–1779, 

Bill.Matthew@nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for 

entrance onto the NIH campus. All 

visitor vehicles, including taxicabs, 

hotel, and airport shuttles will be 

inspected before being allowed on 

campus. Visitors will be asked to show 

one form of identification (for example, 

a government-issued photo ID, driver’s 

license, or passport) and to state the 

purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.ninds.nih.gov, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 25, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–21665 Filed 8–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism, Special 

Emphasis Panel, Review of Resource Grant 

Applications (R24). 

Date: November 3, 2010. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892. 

(Telephone Conference Call.) 

Contact Person: Richard Rippe, PhD, 

Scientific Review Officer, National Institute 

on Alcohol Abuse and Alcoholism, National 

Institutes of Health, 5635 Fishers Lane, Room 

2109, 301–443–8599. rippera@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards., National 

Institutes of Health, HHS) 

Dated: August 25, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–21663 Filed 8–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Initial Review Group; 

Interventions Committee for Disorders 

Involving Children and Their Families. 

Date: October 4–5, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: David I. Sommers, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Room 6154, MSC 9609, 

Bethesda, MD 20892–9606, 301–443–7861, 

dsommers@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Initial Review Group; Mental 

Health Services in Non-Specialty Settings. 

Date: October 12, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Aileen Schulte, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6140, MSC 9608, 

Bethesda, MD 20892–9608, 301–443–1225, 

aschulte@mail.nih.gov. 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 168 / Tuesday, August 31, 2010 / Notices 53321 

Name of Committee: National Institute of 

Mental Health Initial Review Group; 

Interventions Committee for Adult Disorders. 

Date: October 12–13, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: David I. Sommers, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Room 6154, MSC 9606, 

Bethesda, MD 20892–9606, 301–443–7861, 

dsommers@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Initial Review Group; Mental 

Health Services in MH Specialty Settings. 

Date: October 15, 2010. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Dupont Hotel, 1500 New 

Hampshire Avenue, NW., Washington, DC 

20036. 

Contact Person: Marina Broitman, PhD, 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6153, MSC 9608, 

Bethesda, MD 20892–9608, 301–402–8152, 

mbroitma@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: August 25, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–21662 Filed 8–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, Partnerships for Biodefense 

(Vaccines/Immunotherapeutics 3). 

Date: September 27, 2010. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health. 6700B 

Rockledge Drive, Room 3254, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Nancy Lewis Ernst, PhD, 

Scientific Review Official, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–7383, 

nancy.ernst@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, Partnerships for Biodefense 

(Vaccines/Immunotherapeutics 1). 

Date: October 8, 2010. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Room 3254, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Nancy Lewis Ernst, PhD, 

Scientific Review Official, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–7383, 

nancy.ernst@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel, Partnerships for Biodefense 

(Vaccines/Immunotherapeutics 2). 

Date: October 12, 2010. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Room 3254, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Nancy Lewis Ernst, PhD, 

Scientific Review Official, Scientific Review 

Program, Division of Extramural Activities, 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616, 301–451–7383, 

nancy.ernst@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 25, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–21647 Filed 8–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Prospective Grant of a Co-Exclusive 

License: Natural Plant Extracts From 

Incense Cedar as Pest Control Agents 

and Methods for Their Use 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: This is a notice in accordance 

with 35 U.S.C. 209(e) and 37 CFR 

404.7(a)(1)(i) that the Technology 

Transfer Office of the Centers for 

Disease Control and Prevention (CDC), 

located within the Department of Health 

and Human Services (HHS), is 

contemplating the grant of worldwide 

co-exclusive licenses to practice the 

inventions embodied in the patents 

referred to below to Allylix, 

Incorporated and Valent BioSciences 

Corporation, having places of business 

in San Diego, CA and Libertyville, IL, 

respectively. The patent rights in these 

inventions have been assigned to the 

government of the United States of 

America. The patent(s) to be licensed 

are: 

U.S. Pat. No. 7,629,387, ‘‘Compounds for 

Pest Control and Methods for Their Use,’’ 

issued December 8, 2009; and U.S. Pat. No. 

7,129,271, ‘‘Compounds for Pest Control and 

Methods for Their Use,’’ issued October 31, 

2006; and all related foreign patent 

applications. Inventors: Marc C. Dolan, 

Nicholas A. Panella, Joseph J. Karchesy, Gary 

O. Maupin. [CDC Tech. ID No. I–024–00]; 

and U.S. Pat. No. 7,230,033, ‘‘Pest Control 

Compositions and Methods for Their Use,’’ 

issued June 12, 2007. Inventors: Marc C. 

Dolan, Nicholas A. Panella, Gabrielle E. B. 

Dietrich, Joseph J. Karchesy, Gary O. Maupin 

[CDC Tech. ID No. I–028–04]. 

Additional rights to be licensed are: 

‘‘Natural Plant Extracts from Incense Cedar as 

Pest Control Agents and Methods for Their 

Use,’’ submitted February 21, 2008. 

Inventors: Marc C. Dolan, Nicholas A. 

Panella, and Joseph J. Karchesy [CDC Tech. 

ID No. I–019–08]. 

Patent Status: Various. 

Earliest Priority Date: December 8, 

2000. 

The prospective co-exclusive licenses 

will be royalty-bearing and will comply 

with the terms and conditions of 35 

U.S.C. 209 and 37 CFR 404.7. 

Technology 

This technology identifies biologically 

active fractions of essential oil of Alaska 

yellow cedar which are insecticidal and 

acaricidal. These natural compounds 

were found to be active for up to 11 


srobinson on DSKHWCL6B1PROD with NOTICES